SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Positive Phase II Data for Eltoprazine

NEW YORK, NY / ACCESSWIRE / December 15, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS).

The report is available here: AMBS December 2015 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“On December 8, 2015, AMBS announced positive data for Eltoprazine in a Phase II clinical trial of elderly patients with Alzheimer’s dementia who show aggression. Eltoprazine is a selective 5HT1a/1b partial agonist in development by Amarantus for the treatment Parkinson’s Disease Levodopa-Induced Dyskinesia, and is now poised for further clinical development as a symptomatic treatment in adult ADHD and Alzheimer’s aggression,” stated Ajay Tandon, CEO of SeeThruEquity. “We are maintaining our 12-month price target of $45.34 per share.”

Additional highlights from the note are as follows:

Positive Phase II Data for Eltoprazine

On December 8, Amarantus announced positive data for Eltoprazine in a Phase II clinical trial of elderly patients with Alzheimer’s dementia who are experiencing aggressive behavior.

– Of the 20 subjects randomized to receive Eltoprazine, two dropped out during the placebo run-in phase, one because of fatal lung infection, the other subject refusing to eat or drink. One subject was prematurely withdrawn because of physical deterioration due to lung carcinoma. One subject had to be excluded from the efficacy analysis because of an erratic dosing regimen.

– Clinically significant reductions in aggressive behavior in Eltoprazine-treated subjects were especially apparent from the descriptions in the case summaries, which were partly substantiated by the scorings on the Social Dysfunction and Aggression Scale.

Conclusion: Phase II tests showed that using a dosing regimen with phases of gradual dose increases followed by reduction, Eltoprazine appeared safe and reasonably well tolerated in a population of demented elderly subjects with aggressive behavior. There are clear hints of anti-aggressive efficacy in more severely aggressive subjects which merit further research. The study design proved feasible and useful. Further research needs to be done into the correlation between overt aggressive events and basal aggression. Measurements of anti-aggressive efficacy should preferably address both components of aggressive behavior.

Continued development of business segments

Amarantus released an investors presentation on December 5, 2015 presenting the status and outlook of the Company. Their Engineered Skin Substitute (ESS) has great potential to replace skin on severe burns and is partnering with the U.S. Army to help expand development. MSPrecise(R) is proving to be an accurate diagnostic and MANF is expected to take part in first-in-human studies in 2017.

Please review important disclosures at www.seethruequity.com.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS’ Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson’s disease levodopa-induced dyskinesia and with the potential to expand into adult ADHD and Alzheimer’s aggression. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF’s discovery.

AMBS’ Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer’s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro).

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 434754